Myeloid-derived suppressor cells in tumor-induced T cell suppression and tolerance

Paolo Serafini, Vincenzo Bronte

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Tumor development is often associated with a deep alteration of normal myelopoiesis, leading to a progressive accumulation of various cellular elements, belonging to myelomonocytic lineage, in the tumor bed, in the blood, and in both primary and secondary lymphoid organs. This heterogeneous pool of cells expresses, in the mouse, the common markers CD11b and Gr-1 (Ly6C/G) and is endowed with the ability to suppress antigen and/or polyclonal-driven T cell immune response. These cells, named myeloid-derived suppressor cells (MDSCs), are mobilized from hematopoietic organs by cytokines and other factors produced by the tumors, as well as by strong activation of the immune system, and have a profound influence on the outcome of the T cell-dependent immune responses. MDSCs can restrain T cell function directly in an antigen-independent manner; however, in vivo, MDSCs can also process and present tumor-associated antigen and can lead to T cell tolerance in an antigen-specific manner. Furthermore, MDSCs seem to be key players in tumor-induced suppressive network that includes T regulatory (Treg) cells, inhibitory natural killer T (NKT) cells, mast cells, Th17, as well as effector T cells. The importance of MDSCs in human malignancies has been demonstrated in recent years and new approaches targeting their suppressive/tolerogenic action are currently being tested in both preclinical model and clinical trials.

Original languageEnglish (US)
Title of host publicationTumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal
PublisherSpringer New York
Pages99-150
Number of pages52
Volume9781489980564
ISBN (Print)9781489980564, 1489980555, 9781489980557
DOIs
StatePublished - Feb 1 2014

Fingerprint

T-Lymphocytes
Neoplasms
Antigens
Myelopoiesis
Natural Killer T-Cells
Neoplasm Antigens
Regulatory T-Lymphocytes
Mast Cells
Immune System
Myeloid-Derived Suppressor Cells
Clinical Trials
Cytokines

Keywords

  • Clinical trials
  • Human myeloid derived suppressor cells
  • MDSC phenotype
  • Mechanisms of action
  • Mouse myeloid derived suppressor cells
  • Tumor derived factors
  • Tumor progression

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Serafini, P., & Bronte, V. (2014). Myeloid-derived suppressor cells in tumor-induced T cell suppression and tolerance. In Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal (Vol. 9781489980564, pp. 99-150). Springer New York. https://doi.org/10.1007/978-1-4899-8056-4_4

Myeloid-derived suppressor cells in tumor-induced T cell suppression and tolerance. / Serafini, Paolo; Bronte, Vincenzo.

Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal. Vol. 9781489980564 Springer New York, 2014. p. 99-150.

Research output: Chapter in Book/Report/Conference proceedingChapter

Serafini, P & Bronte, V 2014, Myeloid-derived suppressor cells in tumor-induced T cell suppression and tolerance. in Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal. vol. 9781489980564, Springer New York, pp. 99-150. https://doi.org/10.1007/978-1-4899-8056-4_4
Serafini P, Bronte V. Myeloid-derived suppressor cells in tumor-induced T cell suppression and tolerance. In Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal. Vol. 9781489980564. Springer New York. 2014. p. 99-150 https://doi.org/10.1007/978-1-4899-8056-4_4
Serafini, Paolo ; Bronte, Vincenzo. / Myeloid-derived suppressor cells in tumor-induced T cell suppression and tolerance. Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal. Vol. 9781489980564 Springer New York, 2014. pp. 99-150
@inbook{15f12aa72513413fb21fde36f4eb09c2,
title = "Myeloid-derived suppressor cells in tumor-induced T cell suppression and tolerance",
abstract = "Tumor development is often associated with a deep alteration of normal myelopoiesis, leading to a progressive accumulation of various cellular elements, belonging to myelomonocytic lineage, in the tumor bed, in the blood, and in both primary and secondary lymphoid organs. This heterogeneous pool of cells expresses, in the mouse, the common markers CD11b and Gr-1 (Ly6C/G) and is endowed with the ability to suppress antigen and/or polyclonal-driven T cell immune response. These cells, named myeloid-derived suppressor cells (MDSCs), are mobilized from hematopoietic organs by cytokines and other factors produced by the tumors, as well as by strong activation of the immune system, and have a profound influence on the outcome of the T cell-dependent immune responses. MDSCs can restrain T cell function directly in an antigen-independent manner; however, in vivo, MDSCs can also process and present tumor-associated antigen and can lead to T cell tolerance in an antigen-specific manner. Furthermore, MDSCs seem to be key players in tumor-induced suppressive network that includes T regulatory (Treg) cells, inhibitory natural killer T (NKT) cells, mast cells, Th17, as well as effector T cells. The importance of MDSCs in human malignancies has been demonstrated in recent years and new approaches targeting their suppressive/tolerogenic action are currently being tested in both preclinical model and clinical trials.",
keywords = "Clinical trials, Human myeloid derived suppressor cells, MDSC phenotype, Mechanisms of action, Mouse myeloid derived suppressor cells, Tumor derived factors, Tumor progression",
author = "Paolo Serafini and Vincenzo Bronte",
year = "2014",
month = "2",
day = "1",
doi = "10.1007/978-1-4899-8056-4_4",
language = "English (US)",
isbn = "9781489980564",
volume = "9781489980564",
pages = "99--150",
booktitle = "Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal",
publisher = "Springer New York",

}

TY - CHAP

T1 - Myeloid-derived suppressor cells in tumor-induced T cell suppression and tolerance

AU - Serafini, Paolo

AU - Bronte, Vincenzo

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Tumor development is often associated with a deep alteration of normal myelopoiesis, leading to a progressive accumulation of various cellular elements, belonging to myelomonocytic lineage, in the tumor bed, in the blood, and in both primary and secondary lymphoid organs. This heterogeneous pool of cells expresses, in the mouse, the common markers CD11b and Gr-1 (Ly6C/G) and is endowed with the ability to suppress antigen and/or polyclonal-driven T cell immune response. These cells, named myeloid-derived suppressor cells (MDSCs), are mobilized from hematopoietic organs by cytokines and other factors produced by the tumors, as well as by strong activation of the immune system, and have a profound influence on the outcome of the T cell-dependent immune responses. MDSCs can restrain T cell function directly in an antigen-independent manner; however, in vivo, MDSCs can also process and present tumor-associated antigen and can lead to T cell tolerance in an antigen-specific manner. Furthermore, MDSCs seem to be key players in tumor-induced suppressive network that includes T regulatory (Treg) cells, inhibitory natural killer T (NKT) cells, mast cells, Th17, as well as effector T cells. The importance of MDSCs in human malignancies has been demonstrated in recent years and new approaches targeting their suppressive/tolerogenic action are currently being tested in both preclinical model and clinical trials.

AB - Tumor development is often associated with a deep alteration of normal myelopoiesis, leading to a progressive accumulation of various cellular elements, belonging to myelomonocytic lineage, in the tumor bed, in the blood, and in both primary and secondary lymphoid organs. This heterogeneous pool of cells expresses, in the mouse, the common markers CD11b and Gr-1 (Ly6C/G) and is endowed with the ability to suppress antigen and/or polyclonal-driven T cell immune response. These cells, named myeloid-derived suppressor cells (MDSCs), are mobilized from hematopoietic organs by cytokines and other factors produced by the tumors, as well as by strong activation of the immune system, and have a profound influence on the outcome of the T cell-dependent immune responses. MDSCs can restrain T cell function directly in an antigen-independent manner; however, in vivo, MDSCs can also process and present tumor-associated antigen and can lead to T cell tolerance in an antigen-specific manner. Furthermore, MDSCs seem to be key players in tumor-induced suppressive network that includes T regulatory (Treg) cells, inhibitory natural killer T (NKT) cells, mast cells, Th17, as well as effector T cells. The importance of MDSCs in human malignancies has been demonstrated in recent years and new approaches targeting their suppressive/tolerogenic action are currently being tested in both preclinical model and clinical trials.

KW - Clinical trials

KW - Human myeloid derived suppressor cells

KW - MDSC phenotype

KW - Mechanisms of action

KW - Mouse myeloid derived suppressor cells

KW - Tumor derived factors

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=84930023844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930023844&partnerID=8YFLogxK

U2 - 10.1007/978-1-4899-8056-4_4

DO - 10.1007/978-1-4899-8056-4_4

M3 - Chapter

AN - SCOPUS:84930023844

SN - 9781489980564

SN - 1489980555

SN - 9781489980557

VL - 9781489980564

SP - 99

EP - 150

BT - Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal

PB - Springer New York

ER -